Skip to main content
倍益康 logo

倍益康 — Investor Relations & Filings

Ticker · 920199 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 360 across all filing types
Latest filing 2025-01-02 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920199

About 倍益康

https://www.qlbeoka.com/

Beiyikang focuses on the research, development, and manufacturing of rehabilitation and physical therapy equipment. The company integrates professional medical technology with consumer-oriented health solutions. Its product lineup features percussive massage devices, oxygen concentrators, blood pressure monitors, and specialized physical therapy instruments for pain relief and muscle recovery. By utilizing advanced manufacturing processes and technological innovation, Beiyikang delivers products for sports recovery, clinical rehabilitation, and personal health management. The company prioritizes the incorporation of smart technology into its hardware to improve therapeutic outcomes and user experience across its range of recovery and wellness devices.

Recent filings

Filing Released Lang Actions
关于产品取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about obtaining medical device registration certificates for two products. It includes details about the products, their registration numbers, validity periods, and the impact on the company's business and financials. The document is relatively short (1661 characters) and does not contain detailed financial statements or comprehensive report data. It is an announcement of a regulatory approval event rather than a financial report or detailed management discussion. There is no indication of it being an annual report, interim report, earnings release, or any other detailed financial filing. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2025-01-02 Chinese
投资者关系活动记录表
Investor Presentation Classification · 95% confidence The document is an investor relations activity record from Sichuan Qianli Beiyikang Medical Technology Co., Ltd. It details a media interview and site visit conducted on December 6, 2024, with the company's chairman and other representatives. The content includes responses to questions about product registrations, market strategies, production capacity expansion, innovation, overseas market plans, potential mergers and acquisitions, and investor returns. There are no financial statements, earnings highlights, or formal report disclosures. The document is a detailed record of an investor relations event rather than a financial report, earnings release, or regulatory filing. It fits best under the category of Investor Presentation (IP), as it provides detailed information for investors focusing on company strategy, products, and market position.
2024-12-08 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock price fluctuations for the company Sichuan Qianli Beiyikang Medical Technology Co., Ltd. It details the stock price movement over two trading days, the company's investigation into possible causes, and confirms no undisclosed material information exists. It also includes a risk warning to investors. The document is regulatory in nature, related to stock trading compliance and disclosure obligations under the Beijing Stock Exchange rules. It does not contain financial statements, audit information, or detailed financial results. It is not a report publication announcement since it contains substantive disclosure about stock price abnormality and company statements. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-11-27 Chinese
2024年第三季度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of a dividend distribution plan for the third quarter of 2024. It details the dividend amount, the record date, the ex-dividend date, tax treatment, and payment method. It references a shareholders' meeting resolution approving the plan. The content is focused on dividend distribution specifics rather than financial results or reports. The document length is short (1739 characters) and it is clearly an announcement of dividend amount and payment details, fitting the definition of a Notice of Dividend Amount (DIV).
2024-11-13 Chinese
2024年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2024 second extraordinary general meeting of shareholders of Sichuan Qianli Beiyikang Medical Technology Co., Ltd. It includes details about the meeting date, attendance, voting results, and the approval of a profit distribution plan. The document is an official disclosure of the voting results from a shareholders' meeting, not the meeting materials themselves or a full report. It explicitly states the voting outcomes and legal compliance, which aligns with the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters and is focused on announcing the voting results rather than presenting a full report or presentation.
2024-11-12 Chinese
北京大成（成都）律师事务所关于四川千里倍益康医疗科技股份有限公司2024年第二次临时股东大会的法律意见书
Legal Proceedings Report Classification · 90% confidence The document is a legal opinion letter issued by a law firm regarding the legality and procedures of a company's 2024 second extraordinary general meeting of shareholders. It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or financial performance data, nor is it an announcement of a report publication. It is a legal opinion related to a shareholders' meeting, which is typically classified under regulatory or legal proceedings filings. However, since it is a legal opinion on the shareholders' meeting procedures and voting, it aligns best with Legal Proceedings Report (LTR) rather than other categories like AGM Information or Declaration of Voting Results, as it is a legal opinion rather than the meeting materials or voting results announcement themselves. The document length is 3506 characters, which is relatively short but contains substantive legal content rather than a mere announcement. Therefore, the best fit is Legal Proceedings Report (LTR).
2024-11-12 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.